A phase II study of sulofenur,a novel sulfonylurea,in recurrent epithelial ovarian cancer |
| |
Authors: | Mary ER O'Brien Janet Hardy Sylvia Tan Jackie Walling Brian Peters Sarah Hatty Eve Wiltshaw |
| |
Affiliation: | (1) Dept. of Medicine, Royal Marsden Hospital, Fulham Rd, SW3 6JJ London, UK;(2) Lilly Research Centre Ltd, Surrey, UK |
| |
Abstract: | Summary A total of 16 patients with recurrent epithelial ovarian cancer were treated with sulofenur (LY 186641), a novel oral sulfonylurea. All subjects had received previous chemotherapy. Anaemia occurred in all 16 patients, 14 of whom required a blood transfusion, and 2/16 patients received methylene blue for breathlessness due to methaemaglobinaemia. Treatment was discontinued in 2/16 cases due to rising liver enzyme values, which reverted to normal on cessation of the drug. There was no nausea or alopecia. Only two minor responses were seen. Plasma drug levels were insufficient to result in antitumour activity as extrapolated from animal data. Further studies that attempt to increase the bioavailability and improve the therapeutic index are warranted. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|